Author

Choushi Wang

Broad InstituteORCID 0000-0002-6667-1689Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Ping MuiD· 2 shared Siyuan ChengiD· 2 shared Yuyin JiangiD· 2 shared Ariella B. HankeriD· 1 shared Atreyi MukherjiiD· 1 shared Carla R. TiradoiD· 1 shared Carlos L. ArteagaiD· 1 shared Catherine Yijia Zhang· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ping MuORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 23, 2025

Graded Notch Signaling Functions as a Rheostat of Lineage Plasticity and Therapy Resistance in Prostate Cancer

Yuyin Jiang, Siyuan Cheng, Catherine Yijia Zhang…·Ping Mu

This study identifies Notch signaling as a graded rheostat regulating lineage plasticity and therapy resistance in prostate cancer, showing that intermediate Notch activity maintains stem-like progenitor states and that modulating Notch levels can restore drug sensitivity.

DOI 10.1101/2025.11.23.690056

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCancer DiscoveryPeer-reviewedApr 8, 2024

ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers

Yaru Xu, Yuqiu Yang, Zhaoning Wang…·Ping Mu

This study shows ZNF397 loss leads to TET2-driven epigenetic changes, lineage plasticity, and resistance to AR-targeted therapies in AR-dependent cancers, with TET2 inhibitors reversing resistance.

50 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky